Indomethacin Induces Spermidine/Spermine-N1-Acetyltransferase-1 via the Nucleolin-CDK1 Axis and Synergizes with the Polyamine Oxidase Inhibitor Methoctramine in Lung Cancer Cells.

Indomethacin is a non-selective NSAID used against pain and inflammation. Although cyclooxygenase (COX) inhibition is considered indomethacin's primary action mechanism, COX-independent ways are associated with beneficial effects in cancer. In colon cancer cells, the activation of the peroxisome proliferator-activated receptor-γ (PPAR-γ) is related to the increase in spermidine/spermine-N1-acetyltransferase-1 (SSAT-1), a key enzyme for polyamine degradation, and related to cell cycle arrest. Indomethacin increases the SSAT-1 levels in lung cancer cells; however, the mechanism relying on the SSAT-1 increase is unclear. Thus, we asked for the influence of the PPAR-γ on the SSAT-1 expression in two lung cancer cell lines: H1299 and A549. We found that the inhibition of PPAR-γ with GW9662 did not revert the increase in SSAT-1 induced by indomethacin. Because the mRNA of SSAT-1 suffers a pre-translation retention step by nucleolin, a nucleolar protein, we explored the relationship between indomethacin and the upstream translation regulators of SSAT-1. We found that indomethacin decreases the nucleolin levels and the cyclin-dependent kinase 1 (CDK1) levels, which phosphorylates nucleolin in mitosis. Overexpression of nucleolin partially reverts the effect of indomethacin over cell viability and SSAT-1 levels. On the other hand, Casein Kinase, known for phosphorylating nucleolin during interphase, is not modified by indomethacin. SSAT-1 exerts its antiproliferative effect by acetylating polyamines, a process reverted by the polyamine oxidase (PAOX). Recently, methoctramine was described as the most specific inhibitor of PAOX. Thus, we asked if methoctramine could increase the effect of indomethacin. We found that, when combined, indomethacin and methoctramine have a synergistic effect against NSCLC cells in vitro. These results suggest that indomethacin increases the SSAT-1 levels by reducing the CDK1-nucleolin regulatory axis, and the PAOX inhibition with methoctramine could improve the antiproliferative effect of indomethacin.

Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.

Drug combinations are increasingly studied in the field of anticancer agents. Mathematical models, such as Loewe, Bliss, and HSA, are used to interpret drug combinations, while informatics tools help cancer researchers identify the most effective combinations. However, the different algorithms each software uses lead to results that do not always correlate. This study compared the performance of Combenefit (Ver. 2.021) and SynergyFinder (Ver. 3.6) in analyzing drug synergy by studying combinations involving non-steroidal analgesics (celecoxib and indomethacin) and antitumor drugs (carboplatin, gemcitabine, and vinorelbine) on two canine mammary tumor cell lines. The drugs were characterized, their optimal concentration-response ranges were determined, and nine concentrations of each drug were used to make combination matrices. Viability data were analyzed under the HSA, Loewe, and Bliss models. Celecoxib-based combinations showed the most consistent synergistic effect among software and reference models. Combination heatmaps revealed that Combenefit gave stronger synergy signals, while SynergyFinder produced better concentration-response fitting. When the average values of the combination matrices were compared, some combinations shifted from synergistic to antagonistic due to differences in the curve fitting. We also used a simulated dataset to normalize each software's synergy scores, finding that Combenefit tends to increase the distance between synergistic and antagonistic combinations. We conclude that concentration-response data fitting biases the direction of the combination (synergistic or antagonistic). In contrast, the scoring from each software increases the differences among synergistic or antagonistic combinations in Combenefit when compared to SynergyFinder. We strongly recommend using multiple reference models and reporting complete data analysis for synergy claiming in combination studies.

Metabolismo intermediario de Blastocystis spp / Intermediate metabolism of Blastocystis spp

Blastocystis es un stramenopile o cromista, pleomórfico no móvil. Se han identificado diecinue-ve subtipos de este organismo (ST1-ST19). Tiene una presencia a nivel mundial. Este microor-ganismo tiene un metabolismo intermediario anaeróbico. Un aspecto interesante de la bioquími-ca de este stramenopile está dado por la presencia de organelas similares a mitocondrias con un conjunto de rutas: cadena de fosforilación oxidativa incompleta, ciclo de Krebs parcial, metabo-lismo de ácidos grasos (anabolismo y catabolismo), metabolismo de aminoácidos y ensamblaje de proteínas con centros hierro/azufre. El tratamiento se ha basado tradicionalmente en metroni-dazol y otros imidazoles. Sin embargo, hay un número creciente de cepas resistentes a esos medicamentos. La reciente obtención del genoma nuclear y los estudios bioquímicos, proteómi-cos, metabolómicos, interactómicos permitirán el desarrollo racional de nuevos fármacos curati-vos. El objetivo de esta revisión es describir el metabolismo de Blastocystis spp

Blastocystis is a stramenopile or chromist, nonmobile pleomorphic. Nineteen subtypes of this organism (ST1-ST19) have been identified worldwide. This microorganism has an intermediate anaerobic metabolism. An interesting aspect of the biochemistry of this stramenopile is given by the presence of mitochondrial-like organelles with a set of pathways: incomplete oxidative phos-phorylation chain, partial Krebs cycle, fatty acid metabolism (anabolism and catabolism), amino acid metabolism and protein assembly with iron / sulfur centers. Treatment has traditionally been based on metronidazole and other imidazoles. However, there are a growing number of strains resistant to these drugs. The recent obtaining of the nuclear genome and the biochemical, proteomic, metabolomic and interactomic studies will allow the rational development of new curative drugs. The objective of this review is to describe the metabolism of Blastocystis spp.

Tissue Distribution of Kir7.1 Inwardly Rectifying K+ Channel Probed in a Knock-in Mouse Expressing a Haemagglutinin-Tagged Protein.

Kir7.1 encoded by the Kcnj13 gene in the mouse is an inwardly rectifying K+ channel present in epithelia where it shares membrane localization with the Na+/K+-pump. Further investigations of the localisation and function of Kir7.1 would benefit from the availability of a knockout mouse, but perinatal mortality attributed to cleft palate in the neonate has thwarted this research. To facilitate localisation studies we now use CRISPR/Cas9 technology to generate a knock-in mouse, the Kir7.1-HA that expresses the channel tagged with a haemagglutinin (HA) epitope. The availability of antibodies for the HA epitope allows for application of western blot and immunolocalisation methods using widely available anti-HA antibodies with WT tissues providing unambiguous negative control. We demonstrate that Kir7.1-HA cloned from the choroid plexus of the knock-in mouse has the electrophysiological properties of the native channel, including characteristically large Rb+ currents. These large Kir7.1-mediated currents are accompanied by abundant apical membrane Kir7.1-HA immunoreactivity. WT-controlled western blots demonstrate the presence of Kir7.1-HA in the eye and the choroid plexus, trachea and lung, and intestinal epithelium but exclusively in the ileum. In the kidney, and at variance with previous reports in the rat and guinea-pig, Kir7.1-HA is expressed in the inner medulla but not in the cortex or outer medulla. In isolated tubules immunoreactivity was associated with inner medulla collecting ducts but not thin limbs of the loop of Henle. Kir7.1-HA shows basolateral expression in the respiratory tract epithelium from trachea to bronchioli. The channel also appears basolateral in the epithelium of the nasal cavity and nasopharynx in newborn animals. We show that HA-tagged Kir7.1 channel introduced in the mouse by a knock-in procedure has functional properties similar to the native protein and the animal thus generated has clear advantages in localisation studies. It might therefore become a useful tool to unravel Kir7.1 function in the different organs where it is expressed.

[Inflammasome: activation mechanisms]. / El inflamasoma: mecanismos de activación.

Inflammation is a rapid biologic response of the immune system in vascular tissues, directed to eliminate stimuli capable of causing damage and begin the process of repair. The macromolecular complexes known as "inflammasomes" are formed by a receptor, either NOD (NLR) or ALR, the receptor absent in melanoma 2 (AIM2). In addition, the inflammasome is formed by the speck-like protein associated to apoptosis (ASC) and procaspase-1, that may be activated by variations in the ionic and intracellular and extracellular ATP concentrations; and the loss of stabilization of the fagolisosomme by internalization of insoluble crystals and redox mechanisms. As a result, there is activation of the molecular platform and the processing of inflammatory prointerleukins to their active forms. There are two modalities of activation of the inflammasome: canonical and non-canonical, both capable of generating effector responses. Recent data associate NLRP 3, IL-1ß and IL-18 in the pathogenesis of a variety of diseases, including atherosclerosis, type II diabetes, hyperhomocysteinemia, gout, malaria and hypertension. The inflammasome cascade is emerging as a new chemotherapeutic target in these diseases. In this review we shall discuss the mechanisms of activation and regulation of the inflammasome that stimulate, modulate and resolve inflammation.

El inflamasoma: mecanismos de activación / Inflammasome: activation mechanisms

La inflamación es una respuesta biológica rápida del sistema inmune en tejidos vasculares, dirigida a eliminar estímulos capaces de producir daño y a iniciar la curación y la reparación. Los complejos macromoleculares denominados inflamasomas están constituidos por un receptor NOD (NLR), un receptor de AIM2 (ausente en melanoma 2) el ALR, la proteína tipo punto asociada a apoptosis (ASC) y la procaspasa-1, los cuales pueden ser activados por variación en la concentración iónica y de ATP intracelular y extracelular, por desestabilización del fagolisosoma, por internalización de cristales insolubles y por mecanismos de oxidoreducción, lo cual permitirá la activación de la plataforma molecular y el consiguiente procesamiento de las prointerleuquinas inflamatorias a sus formas activas. En la actualidad existen dos nodos de señalización utilizados por los inflamasomas: canónica y no canónica para generar respuestas efectoras. Datos recientes vinculan al inflamasoma NLRP3, la IL-1b y a la IL-18, en el desarrollo y evolución de enfermedades tales como: ateroesclerosis, diabetes tipo II, hiperhomocisteinemia, gota, malaria e hipertensión arterial e identificaron esta cascada, como un blanco quimioterapéutico ideal para la prevención de estas patologías. En esta revisión se discutirán los mecanismos de activación y regulación del inflamasoma que estimulan, modulan y resuelven los procesos inflamatorios.

Inflammation is a rapid biologic response of the immune system in vascular tissues, directed to eliminate stimuli capable of causing damage and begin the process of repair. The macromolecular complexes known as “inflammasomes” are formed by a receptor, either NOD (NLR) or ALR, the receptor absent in melanoma 2 (AIM2). In addition, the inflammasome is formed by the speck-like protein associated to apoptosis (ASC) and procaspase-1, that may be activated by variations in the ionic and intracellular and extracellular ATP concentrations; and the loss of stabilization of the fagolisosomme by internalization of insoluble crystals and redox mechanisms. As a result, there is activation of the molecular platform and the processing of inflammatory prointerleukins to their active forms. There are two modalities of activation of the inflammasome: canonical and non-canonical, both capable of generating effector responses. Recent data associate NLRP 3, IL-1b and IL-18 in the pathogenesis of a variety of diseases, including atherosclerosis, type II diabetes, hyperhomocysteinemia, gout, malaria and hypertension. The inflammasome cascade is emerging as a new chemotherapeutic target in these diseases. In this review we shall discuss the mechanisms of activation and regulation of the inflammasome that stimulate, modulate and resolve inflammation.

Las glándulas salivales de dos flebotominos vectores de Leishmania: Lutzomyia migonei (França) y Lutzomyia ovallesi (Ortiz) (Diptera: Psychodidae) / The salivary glands of two sand fly vectors of Leishmania: Lutzomyia migonei (França) and Lutzomyia ovallesi (Ortiz)

Introducción. La leishmaniasis es una enfermedad transmitida por la inoculación intradérmica de promastigotes de Leishmania (Kinetoplastida: Trypanosomatidae) junto con la saliva del vector durante la picada de un flebotomino infectado.Objetivo. Comparar las glándulas salivales de Lutzomyia ovallesi (Ortiz, 1952) y Lutzomyia migonei (França, 1920) (Diptera: Psychodidae) vectores de Leishmania en América del Sur.Materiales y métodos. Se analizaron los perfiles proteicos por SDS-PAGE de las glándulas salivales de estas dos especies en los diferentes grupos y tiempos posteriores a la alimentación. Se evaluó la presencia de anticuerpos producidos en los ratones inmunizados por la picaduras de L. ovallesi y L. migonei por inmunotransferencia. Resultados. Los resultados mostraron que no hay cambio aparente en la cinética de expresión de las proteínas salivales, inducidas por los distintos estados fisiológicos, en las dos especies, presentándose variaciones cualitativas y cuantitativas. Los perfiles proteicos revelaron alrededor de 16 a 18 polipéptidos, con pesos moleculares entre 6 a 180 kDa. Los resultados mostraron proteínas específicas para L. migonei y L. ovallesi. También, se detectaron anticuerpos producidos en los ratones inmunizados por las picaduras de ambas especies, contra proteínas específicas de las glándulas salivales.Conclusión. Los resultados proveen información básica sobre las proteínas salivales de las especies L. migonei y L. ovallesi que podrían ser importantes en futuros estudios como posible herramienta para estudiar los factores de riesgos en la población y en otros huéspedes vertebrados.

Introduction. Leishmaniasis is a vector-borne disease transmitted by the intradermal inoculation of Leishmania (Kinetoplastida: Trypanosomatidae) promastigotes together with saliva during the bite of an infected sand fly.Objective. The salivary glands were compared from two vector species, Lutzomyia ovallesi (Ortiz,1952) and Lutzomyia migonei (França,1920) (Diptera: Psychodidae). Material and methods. Protein profiles by SDS PAGE of salivary glands were compared among species as well as their development at several times post feeding. First, mice were immunized to salivary proteins by exposure to biting by L. ovallesi and of L. migonei. Antibodies in these mice against salivary gland-specific proteins were evaluated by immunoblotting.Results. No apparent change was revealed in the kinetic expression of salivary proteins induced by the different physiological states post feeding. Qualitative and quantitative variations were detected in16-18 polypeptides with molecular weights ranging from 6 to 180 kDa. Species-specific proteins were demonstrated for L. migonei and L. ovallesi. In addition, antibodies against salivary gland specific proteins were found in mice immunized by the saliva of both species. Conclusion. Basic information was obtained concerning the nature of salivary gland proteins of L. migonei and L. ovallesi. This information helps to elucidate the role of salivary proteins and their potential as effective tools in screening risk factors in human and other vertebrate hosts.

The salivary glands of two sand fly vectors of Leishmania: Lutzomyia migonei (França) and Lutzomyia ovallesi (Ortiz)(Diptera: Psychodidae).

INTRODUCTION: Leishmaniasis is a vector-borne disease transmitted by the intradermal inoculation of Leishmania (Kinetoplastida: Trypanosomatidae) promastigotes together with saliva during the bite of an infected sand fly. OBJECTIVE: The salivary glands were compared from two vector species, Lutzomyia ovallesi (Ortiz,1952) and Lutzomyia migonei (França,1920) (Diptera: Psychodidae). MATERIAL AND METHODS: Protein profiles by SDS PAGE of salivary glands were compared among species as well as their development at several times post feeding. First, mice were immunized to salivary proteins by exposure to biting by L. ovallesi and of L. migonei. Antibodies in these mice against salivary gland-specific proteins were evaluated by immunoblotting. RESULTS: No apparent change was revealed in the kinetic expression of salivary proteins induced by the different physiological states post feeding. Qualitative and quantitative variations were detected in16-18 polypeptides with molecular weights ranging from 6 to 180 kDa. Species-specific proteins were demonstrated for L. migonei and L. ovallesi. In addition, antibodies against salivary gland specific proteins were found in mice immunized by the saliva of both species. CONCLUSION: Basic information was obtained concerning the nature of salivary gland proteins of L. migonei and L. ovallesi. This information helps to elucidate the role of salivary proteins and their potential as effective tools in screening risk factors in human and other vertebrate hosts.